AIM
KPTI icon

Assured Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Assured Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,656
Closed -$233K – 464
2019
Q1 		$233K Buy
+2,656
New +$294K ﹤0.01% 770
2018
Q4 		– Sell
-370
Closed -$94K – 1234
2018
Q3 		$94K Buy
+370
New +$102K ﹤0.01% 1053

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Assured Investment Management's KPTI Position: Q2 2019 in Review

Assured Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2019, closing a stake of 2,656 shares — an estimated $233K sold.

Assured Investment Management first reported a position in KPTI in Q3 2018 and held it in 2 quarters. The position peaked at $233K in Q1 2019. 103 funds tracked by Wall St. Rank hold KPTI as of Q2 2019.

  • Assured Investment Management reported no remaining Karyopharm Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 2,656 Karyopharm Therapeutics shares in Q2 2019, an estimated $233K.
  • Assured Investment Management first reported a position in Karyopharm Therapeutics in Q3 2018 and held it in 2 quarters.
  • Assured Investment Management's Karyopharm Therapeutics position peaked at $233K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.